Longeveron Inc (LGVN) Stock Price, Quote & News

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 470 2550

Website: longeveron.com

Address:

Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States

Jrappaport14 Apr. 2 at 8:16 PM

$LGVN 7 more days trading above $1 and we will regain NASDAQ compliance

0 · Reply

sniky25 Apr. 2 at 2:11 PM

$LGVN we are up today with extremely low volume. Must mean something good. Also, good thing to be in this when it's not under the radar yet. Bearish? Sorry but I don't think so

1 · Reply

Fdonald2 Apr. 2 at 1:57 PM

$USO -----> buy now $LGVN another 100% soon

0 · Reply

Fdonald2 Apr. 2 at 1:24 PM

$SPY ------> $LGVN 100% up soon!

0 · Reply

Fdonald2 Apr. 2 at 3:40 AM

$SPY ..... the next big thing ---> $LGVN Source Avg. Target Upside Notes MarketBeat $3.00 +167.86% 2 analysts, consensus Hold (1 Buy, 1 Sell) StockAnalysis $3.00 +235.76% 1 analyst, Strong Buy Zacks $6.61 +581.44% 4 analysts, Strong Buy across the board Interpretation: Analysts who do cover LGVN are extremely bullish — but coverage is thin, and microcap biotech targets are notoriously volatile. 📌 2. Technical Outlook: Strong Buy (Short-Term) According to StockScan’s technical model: 12 Buy signals 0 Sell signals 5 Neutral RSI ~64 → not overbought ADX ~48 → strong trend All major moving averages = Buy Interpretation: Momentum is currently bullish, and the trend strength is real. This aligns with typical microcap biotech behavior before catalysts or capital events.

0 · Reply

annee33 Apr. 1 at 3:06 PM

$LGVN a couple of big buys here, could breakout in a hurry

0 · Reply

Fdonald2 Mar. 31 at 11:26 PM

$LGVN easy $2 soon

0 · Reply

milk25 Mar. 31 at 4:51 PM

$OCGN $LGVN $AIB

0 · Reply

Lucasj0504 Mar. 30 at 6:54 PM

$LGVN get in now before you’re too late

0 · Reply

Kingdaley Mar. 30 at 4:22 PM

$LGVN going to run again

0 · Reply

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Mar 17, 2026, 3:16 PM EDT - 18 days ago

Longeveron Braces For Q4 Results Following Recent Funding Boost

Mar 11, 2026, 4:05 PM EDT - 24 days ago

Longeveron Announces Closing of Private Placement of up to $30 Million

Mar 10, 2026, 3:58 PM EDT - 25 days ago

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Feb 25, 2026, 11:05 AM EST - 5 weeks ago

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Feb 13, 2026, 4:30 PM EST - 7 weeks ago

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Feb 5, 2026, 9:15 AM EST - 2 months ago

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Jan 29, 2026, 9:15 AM EST - 2 months ago

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Dec 29, 2025, 9:15 AM EST - 3 months ago

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Dec 2, 2025, 9:15 AM EST - 4 months ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 1, 2025, 12:00 PM EST - 4 months ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 4 months ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 12, 2025, 9:05 AM EST - 5 months ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Oct 27, 2025, 9:15 AM EDT - 5 months ago

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 6, 2025, 9:15 AM EDT - 6 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 22, 2025, 9:15 AM EDT - 6 months ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 3, 2025, 4:05 PM EDT - 7 months ago

Longeveron® Announces Key Leadership Updates

Aug 20, 2025, 9:15 AM EDT - 8 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:15 PM EDT - 8 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 8 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Aug 5, 2025, 9:15 AM EDT - 8 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Jul 21, 2025, 9:15 AM EDT - 9 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 8, 2025, 9:15 AM EDT - 9 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jun 26, 2025, 9:05 AM EDT - 10 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 24, 2025, 6:30 AM EDT - 10 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 9, 2025, 9:15 AM EDT - 10 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 20, 2025, 9:15 AM EDT - 11 months ago

Longeveron® to Attend BIO International Convention 2025

May 12, 2025, 7:15 AM EDT - 11 months ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 8, 2025, 4:05 PM EDT - 11 months ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 2, 2025, 8:30 AM EDT - 1 year ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 5, 2025, 9:25 AM EST - 1 year ago

Longeveron® to Present at the 37th Annual Roth Conference

Feb 28, 2025, 4:04 PM EST - 1 year ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 18, 2025, 9:25 AM EST - 1 year ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 1 year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jrappaport14 Apr. 2 at 8:16 PM

$LGVN 7 more days trading above $1 and we will regain NASDAQ compliance

0 · Reply

sniky25 Apr. 2 at 2:11 PM

$LGVN we are up today with extremely low volume. Must mean something good. Also, good thing to be in this when it's not under the radar yet. Bearish? Sorry but I don't think so

1 · Reply

Fdonald2 Apr. 2 at 1:57 PM

$USO -----> buy now $LGVN another 100% soon

0 · Reply

Fdonald2 Apr. 2 at 1:24 PM

$SPY ------> $LGVN 100% up soon!

0 · Reply

Fdonald2 Apr. 2 at 3:40 AM

0 · Reply

annee33 Apr. 1 at 3:06 PM

$LGVN a couple of big buys here, could breakout in a hurry

0 · Reply

Fdonald2 Mar. 31 at 11:26 PM

$LGVN easy $2 soon

0 · Reply

milk25 Mar. 31 at 4:51 PM

$OCGN $LGVN $AIB

0 · Reply

Lucasj0504 Mar. 30 at 6:54 PM

$LGVN get in now before you’re too late

0 · Reply

Kingdaley Mar. 30 at 4:22 PM

$LGVN going to run again

0 · Reply

Lucasj0504 Mar. 30 at 3:12 PM

$LGVN volume coming in…

0 · Reply

Drunk1973 Mar. 29 at 12:04 AM

$LGVN time to short this turd

1 · Reply

Lucasj0504 Mar. 27 at 8:35 PM

$LGVN way too quiet in here, something is bound to happen any second

0 · Reply

ImCleep Mar. 26 at 6:04 AM

$LGVN Additional grace period to reach compliance until 21 september, huge for us. Chart being above 200ma on the daily i only see upside from here

0 · Reply

Jrappaport14 Mar. 25 at 9:21 PM

$LGVN granted a 180 day extension from NASDAQ to regain compliance… with positive trial readouts over the summer we might never have to think about a R/S again https://d18rn0p25nwr6d.cloudfront.net/CIK-0001721484/bd6a0f9c-544e-469a-9b06-9c21b590f394.pdf

0 · Reply

Lucasj0504 Mar. 25 at 3:41 PM

$LGVN all we need is volume baby I can wait

0 · Reply

Kingdaley Mar. 25 at 12:13 AM

$LGVN very

0 · Reply

Lucasj0504 Mar. 24 at 8:28 PM

$LGVN rs cancelled. Going to run rest of week.

0 · Reply

Holymoly1269 Mar. 24 at 6:20 PM

$LGVN 50 cents

0 · Reply

Lucasj0504 Mar. 24 at 2:44 PM

$LGVN huge buys

0 · Reply

Kingdaley Mar. 23 at 5:24 PM

$LGVN this is the bottom it’ll only go up from here

0 · Reply

Waleedmusa Mar. 23 at 5:03 PM

$LGVN any hope here

0 · Reply

Market Cap	24.90M
Revenue (ttm)	1.20M
Net Income (ttm)	-22.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,891.67%
Debt to Equity Ratio	0.03

Volume	1,195,300
Avg Vol	6,686,878
Day's Range	N/A - N/A
Shares Out	23.27M
Stochastic %K	72%
Beta	-0.18
Analysts	Strong Sell
Price Target	$6.61